Children's Tumor Foundation logo
World's Largest Neurofibromatosis Conference to be Held in Washington, D.C.
03 juin 2014 16h52 HE | Children's Tumor Foundation
NEW YORK, June 3, 2014 (GLOBE NEWSWIRE) -- The Children's Tumor Foundation (CTF) is hosting the 2014 NF Conference/Forum, the largest worldwide meeting dedicated entirely to neurofibromatosis (NF), a...
Children's Tumor Foundation Announces Historic New Initiative in Neurofibromatosis Research
10 mars 2014 11h33 HE | Children's Tumor Foundation
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- The Children's Tumor Foundation, the leading non-governmental organization dedicated to neurofibromatosis (NF) research, announced today an important new...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2013 08h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
06 août 2013 07h29 HE | Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, Raptor's Executive Vice President, Strategy and Chief Operating...
Genetic Alliance and Inspire Partner on Rare and Genetic Disease Support Community
28 févr. 2013 07h00 HE | Inspire
PRINCETON, NJ--(Marketwire - Feb 28, 2013) -  Inspire, the patient engagement company, announced today that Genetic Alliance will partner with Inspire to create the Inspire/Genetic Alliance...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
07 janv. 2013 07h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
24 déc. 2012 07h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
LaVoie Group Logo
LaVoie Group Issues White Paper: Solving the Unique Problems of Orphan Drug Communications
18 oct. 2012 10h40 HE | LaVoie Health Science
Cambridge, MA, Oct. 18, 2012 (GLOBE NEWSWIRE) -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), the acknowledged leader in life science, medtech and pharmaceutical communications, today...
Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
01 mai 2012 07h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
30 avr. 2012 08h00 HE | Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...